Amedisys Other Operating Expenses from 2010 to 2024
| AMED Stock | USD 90.78 0.18 0.20% |
Other Operating Expenses | First Reported 1993-12-31 | Previous Quarter 509 M | Current Value 677.4 M | Quarterly Volatility 193.7 M |
Check Amedisys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amedisys main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.7 M, Interest Expense of 32.8 M or Selling General Administrative of 819.1 M, as well as many exotic indicators such as Price To Sales Ratio of 0.86, Dividend Yield of 0.0023 or PTB Ratio of 2.57. Amedisys financial statements analysis is a perfect complement when working with Amedisys Valuation or Volatility modules.
Amedisys | Other Operating Expenses |
Latest Amedisys' Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Amedisys over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Amedisys. It is also known as Amedisys overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Amedisys' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amedisys' overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Amedisys Other Operating Expenses Regression Statistics
| Arithmetic Mean | 1,543,421,920 | |
| Geometric Mean | 1,179,000,444 | |
| Coefficient Of Variation | 34.92 | |
| Mean Deviation | 393,663,115 | |
| Median | 1,507,430,000 | |
| Standard Deviation | 538,887,606 | |
| Sample Variance | 290399.9T | |
| Range | 2.1B | |
| R-Value | 0.73 | |
| Mean Square Error | 145377.7T | |
| R-Squared | 0.54 | |
| Significance | 0 | |
| Slope | 88,149,374 | |
| Total Sum of Squares | 4065597.9T |
Amedisys Other Operating Expenses History
About Amedisys Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Amedisys income statement, its balance sheet, and the statement of cash flows. Amedisys investors use historical funamental indicators, such as Amedisys's Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Amedisys investors may use each financial statement separately, they are all related. The changes in Amedisys's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Amedisys's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Amedisys Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Amedisys. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 2 B | 2.1 B |
Pair Trading with Amedisys
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.Moving together with Amedisys Stock
| 0.9 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
Moving against Amedisys Stock
| 0.8 | HIMS | Hims Hers Health Financial Report 13th of May 2024 | PairCorr |
| 0.69 | ELMD | Electromed | PairCorr |
| 0.59 | BAX | Baxter International Financial Report 25th of April 2024 | PairCorr |
| 0.58 | HOLX | Hologic Financial Report 6th of May 2024 | PairCorr |
| 0.55 | ALC | Alcon AG Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.
The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Amedisys Correlation against competitors. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.40) | Earnings Share (0.30) | Revenue Per Share 68.603 | Quarterly Revenue Growth 0.016 | Return On Assets 0.0598 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.